Loading clinical trials...
Loading clinical trials...
Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS
Conditions
Interventions
Placebo
Ocrelizumab
+1 more
Locations
84
United States
Phoenix Neurological Associates Ltd
Phoenix, Arizona, United States
Barrow Neurological Institute
Phoenix, Arizona, United States
East Bay Physicians Med Group;Sutter East Bay Med Foundation
Berkeley, California, United States
University of California San Francisco
San Francisco, California, United States
Advanced Neurology of Colorado, LLC
Fort Collins, Colorado, United States
Bradenton Research Center
Bradenton, Florida, United States
Start Date
July 17, 2008
Primary Completion Date
March 9, 2012
Completion Date
November 8, 2023
Last Updated
December 31, 2024
NCT05359653
NCT06390930
NCT03401879
NCT06389968
NCT05834855
NCT06413602
Lead Sponsor
Genentech, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions